# US 2012/0251482 A1 · Use for improving 5-ht function and enos expression of kmups amine salts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251482 A1
- Document ID: US20120251482A1
- Status: Published application
- Kind: A1
- Application number: 13/235,971
- Filed: 2011-09-19
- Published: 2012-10-04
- Earliest claimed: 2011-03-30
- Assignees: Kaohsiung Medical University
- Inventors: Ing-Jun Chen
- Web page: https://patentgrep.com/patent/US20120251482A1

## CPC

- C07D 473/08: with methyl radicals in positions 1 and 3, e.g. theophylline
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- C08F 26/06: by a heterocyclic ring containing nitrogen
- C08L 5/00: Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

The synthesized piperazium salt of KMUPs disclosed in the present invention is characterized by presented pharmaceutics having functions to improve 5-HT function and eNOS expression of KMUPS in lung diseases, such as proliferation, obliteration, pulmonary artery hypertension. The pharmaceutical composition for inhibiting monocrotaline (MCT)-induced proliferation of pulmonary artery includes an effective amount of a complex salt of formula (I): wherein R2 and R4 are each selected independently from the group consisting of a C1˜C5 alkoxy group, a hydrogen, a nitro group, and a halogen atom; RX contains a carboxylic group donated from one selected from a group consisting of a Statin, a Co-polymer, a poly-γ-polyglutamic acid (γ-PGA) derivative and sodium CMC; and −RX substituent is an anion of the carboxylic group carrying a negative charge; and a pharmaceutically accepted carrier.

## Claims

### Claim 1

A complex compound for inhibiting MCT-induced pulmonary artery proliferation, comprising a KMUPs amine salt represented by formula I:
wherein: R2 and R4 are selected independently from a group consisting of a C1˜C5 alkoxy group, a hydrogen, a nitro group, and a halogen atom;
RX includes a carboxylic group selected from a group consisting of a Statin, a sodium carboxyl methylcellulose (sodium CMC), a poly-γ-polyglutamic acid (γ-PGA) derivative and a Co-polymer; and
−RX is an anion of a carboxylic group donated from one selected from a group consisting of a Statin, a sodium CMC, a γ-PGA derivative and a Co-polymer.

### Claim 2 (depends on 1)

A complex compound as claimed in claim 1, wherein the halogen atom is one selected from a group consisting of a fluorine, a chlorine, a bromine and an iodine.

### Claim 3 (depends on 1)

A complex compound as claimed in claim 1, wherein the KMUPs amine salt comprising one selected from a group consisting of a KMUP-1-amine salt, a KMUP-2-amine salt, a KMUP-3-amine salt and a KMUP-4-amine salt.

### Claim 4 (depends on 2)

A complex compound as claimed in claim 2, wherein the KMUP-1-amine salt includes a 7-[2-[4-(2-chlorophenyl)piperazinyl]ethyl]-1,3-dimethyl-xanthine-amine salt.

### Claim 5 (depends on 2)

A complex compound as claimed in claim 2, wherein the KMUP-2-amine salt includes a 7-[2-[4-(2-methoxybenzene)piperazinyl]ethyl]-1,3-dimethyl-xanthine-amine salt.

### Claim 6 (depends on 2)

A complex compound as claimed in claim 2, wherein the KMUP-3-amine salt includes a 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1,3-dimethyl-xanthine-amine salt.

### Claim 7 (depends on 2)

A complex compound as claimed in claim 2, wherein the KMUP-3-amine salt includes a 7-[2-[4-(2-nitrobenzene)piperazinyl]ethyl]-1,3-dimethyl-xanthine-amine salt.

### Claim 8 (depends on 1)

A complex compound as claimed in claim 1, wherein the poly-γ-polyglutamic acid (γ-PGA) derivative includes one selected from a group consisting of an alginate sodium, a poly-γ-polyglutamic acid (γ-PGA), a poly-γ-polyglutamic acid sodium (γ-PGA sodium), and a glutamic acid-L-lysine-L-tyrosine.

### Claim 9 (depends on 1)

A complex compound as claimed in claim 1, wherein the Co-polymers includes one selected from a group consisting of a hyaluronic acid a polyacrylic acid, a dextran sulfate, a polymethacrylates (PMMA), an Eudragit, a dextran sulfate, a heparan sulfate, a polylactic acid or polylactide (PLA), a polylactic acid sodium (PLA sodium) and a polyglycolic acid sodium (PGA sodium).

### Claim 10

A pharmaceutical composition for inhibiting MCT-induced pulmonary artery proliferation, comprising an effective amount of a KMUPs amine salt represented by formula I:
wherein: R2 and R4 are selected independently from a group consisting of a C1˜C5 alkoxy group, a hydrogen, a nitro group, and a halogen atom;
RX includes a carboxylic group selected from a group consisting of a Statin, a sodium carboxyl methylcellulose (sodium CMC), a poly-γ-polyglutamic acid (γ-PGA) derivative and a Co-polymer; and
−RX is an anion of a carboxylic group donated from one selected from a group consisting of a Statin, a sodium CMC, a γ-PGA derivative and a Co-polymer.

### Claim 11 (depends on 10)

A pharmaceutical composition as claimed in claim 10, wherein the halogen atom is one selected from a group consisting of a fluorine, a chlorine, a bromine and an iodine.

### Claim 12 (depends on 10)

A pharmaceutical composition as claimed in claim 10, wherein the KMUPs amine salt comprising one selected from a group consisting of a KMUP-1-amine salt, a KMUP-2-amine salt, a KMUP-3-amine salt and a KMUP-4-amine salt.

### Claim 13 (depends on 10)

A pharmaceutical composition as claimed in claim 10, wherein the KMUP-1-amine salt includes a 7-[2-[4-(2-chlorophenyl)piperazinyl]-ethyl]-1,3-dimethyl xanthine-amine salt.

### Claim 14 (depends on 10)

A pharmaceutical composition as claimed in claim 10, wherein the KMUP-2-amine salt includes a 7-[2-[4-(2-methoxybenzene)piperazinyl]-ethyl]-1,3-dimethylxanthine-amine salt.

### Claim 15 (depends on 10)

A pharmaceutical composition as claimed in claim 10, wherein the KMUP-3-amine salt includes a 7-[2-[4-(4-nitrobenzene)piperazinyl]-ethyl]-1,3-dimethylxanthine-amine salt.

### Claim 16 (depends on 10)

A pharmaceutical composition as claimed in claim 10, wherein the KMUP-3-amine salt includes a 7-[2-[4-(2-nitrobenzene)piperazinyl]-ethyl]-1,3-dimethylxanthine-amine salt.

### Claim 17 (depends on 10)

A pharmaceutical composition as claimed in claim 10, wherein the poly-γ-polyglutamic acid (γ-PGA) derivative includes one selected from a group consisting of an alginate sodium, a poly-γ-polyglutamic acid (γ-PGA), a poly-γ-polyglutamic acid sodium (γ-PGA sodium), and a glutamic acid-L-lysine-L-tyrosine.

### Claim 18 (depends on 10)

A pharmaceutical composition as claimed in claim 10, wherein the Co-polymers includes one selected from a group consisting of a hyaluronic acid a polyacrylic acid, a dextran sulfate a heparan sulfate, a polylactic acid or polylactide (PLA), a polylactic acid sodium (PLA sodium) and a polyglycolic acid sodium (PGA sodium).

### Claim 19 (depends on 1)

A method of providing a medical effect for inhibiting MCT-induced pulmonary artery proliferation, the method comprising steps of:
providing a subject in need thereof; and
administering to the subject in need thereof an effective amount of a pharmaceutical composition comprising the complex compound of claim 1.

### Claim 20 (depends on 10)

A method of providing a medical effect for treatment of 5-HT-induced pulmonary artery hypertension, the method comprising steps of:
providing a subject in need thereof; and administered to the subject in need thereof an effective amount of the pharmaceutical composition of claim 10.
